

## Press Release

### Solactive releases Genomics Index based on its NLP engine ARTIS® - underlying the Global X Genomics & Biotechnology ETF [GNOM]

9 April 2019

Solactive is pleased to announce the release of the **Solactive Genomics Index**, which serves as the underlying for the **Global X Genomics & Biotechnology ETF [Ticker: GNOM]**. The ETF enables investors to specifically invest in companies that are pioneers in Genomics. The underlying index tracks the price movements in shares of companies that are active in the fields such as gene editing, genomic sequencing, development and testing of genetic medicine or therapies, and genetic diagnostics or biotechnology. To develop this index, Solactive utilized its **proprietary Natural Language Processing algorithm ARTIS®**.

According to a study published by the market intelligence provider *BIS research center*, genomics technology holds the potential to generate a revenue of USD 140 bn by 2026. This immense revenue forecast implies the tremendous potential that this cutting-edge technology cocoons, and as a sideline, implies the capability it holds to revolutionize not only the entire biotechnology sector but the way humanity treats illnesses.

Companies that are eligible for the index must generate at least 50% of their revenues from genomics-related businesses and/or are classified as "Biotechnology" according to conventional Industries and Economic Sectors classification systems. If a company qualifies for "Biotechnology" classification, Solactive executes a greater in-depth analysis to reveal the candidate's activity in genomics technology. In the next step, Solactive's proprietary **ARTIS®** engine, which screens publicly available information such as financial websites, search engines or company publications using its proprietary a natural language processing algorithm, further refines the prefiltered universe.

**ARTIS®** utilizes advanced algorithms to parse large volumes of public documents evaluating companies' relevancy to various themes or topics. Going beyond a solely qualitative approach, the sophisticated procedure ranks potential index constituents according to proprietary criteria, **not only considering a company's exposure to a theme but also the company's importance to the theme.**

**Solactive AG**  
German Index Engineering  
Guiollettstr. 54  
60325 Frankfurt am Main  
Germany

**Timo Pfeiffer**  
Head of Research  
+49 (69) 719 160-320  
[pfeiffer@solactive.com](mailto:pfeiffer@solactive.com)

**Fabian Colin**  
Head of Sales  
+49 (69) 719 160-220  
[colin@solactive.com](mailto:colin@solactive.com)

**Phil Wiedbrauck**  
PR & Communications  
+49 (69) 719 160-311  
[phil.wiedbrauck@solactive.com](mailto:phil.wiedbrauck@solactive.com)

Timo Pfeiffer, Head of Research of Solactive, comments: *"This index combines two very cutting-edge subjects: one is the topic itself, genomics, which is a megatrend bearing incredible potential. Its innovations will contribute to medical and therefore societal paradigm shifts, paving the way for discoveries in smart technology and personalized medicine. We are very proud to have found a kindred spirit in Global X, which is also a player that dares to disrupt the industry in the space of thematic ETFs."*

The **Global X Genomics & Biotechnology ETF** will be listed on NASDAQ on April 9<sup>th</sup>, 2019.

For further information, please visit: [www.solactive.com](http://www.solactive.com)

## Note to editors

### About Solactive

Solactive AG is an innovative index provider that focuses on the development, calculation and distribution of tailor-made indices across all asset classes. As at January 2019, Solactive AG served approximately 400 clients in Europe, America and Asia, with approximately USD 200 billion invested in products linked to indices calculated by the company globally, primarily via 380 exchange-traded funds from a number of well-known providers. Solactive AG was established in 2007 and is headquartered in Frankfurt.

### Disclaimer

The information in this document does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. Solactive AG and all other companies mentioned in this document are not responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.

Solactive AG, Guiollettstr. 54, 60325 Frankfurt am Main, Germany. Registered Office: Frankfurt am Main, Registration Court: Amtsgericht Frankfurt am Main, HRB: 79986, USt-IdNr.: DE 255 598 976. Management Board: Steffen Scheuble, Christian Grabbe, Christian Vollmuth, and Dirk Urmoneit, Head of Supervisory Board: Dr Felix Mühlhäuser.

**Solactive AG**  
**German Index Engineering**  
Guiollettstr. 54  
60325 Frankfurt am Main  
Germany

**Timo Pfeiffer**  
**Head of Research**  
+49 (69) 719 160-320  
[pfeiffer@solactive.com](mailto:pfeiffer@solactive.com)

**Fabian Colin**  
**Head of Sales**  
+49 (69) 719 160-220  
[colin@solactive.com](mailto:colin@solactive.com)

**Phil Wiedbrauck**  
**PR & Communications**  
+49 (69) 719 160-311  
[phil.wiedbrauck@solactive.com](mailto:phil.wiedbrauck@solactive.com)